Cost-utility of minimally invasive therapies vs. pharmacotherapy as initial therapy for benign prostatic hyperplasia: A Canadian healthcare payer perspective.

Autor:	Sahakyan, Yeva1, Erman, Aysegul1, Bhojani, Naeem2, Chughtai, Bilal3, Zorn, Kevin C.2, Sander, Beate1,4,5, Elterman, Dean S.6 dean.elterman@uhn.ca
Zdroj:	Canadian Urological Association Journal. Apr2023, Vol. 17 Issue 4, p103-110. 8p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu